Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr
Metastatic Melanoma
Explore 99 assets in Metastatic Melanoma →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02027935CT.gov CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr (this asset) | M.D. Anderson Cancer Center | P2 | CCC · 50 |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Cediranib | M.D. Anderson Cancer Center | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Irinotecan | Melanoma and Skin Cancer Trials Limited | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Iovance Biotherapeutics, Inc. | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | CCC · 55 |
| Uveal Melanoma | — | P1 | CC · 41 |
| Cancer | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd8-t-cells-transduced-with-mage-a1-directed-tcr-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →